Please login to the form below
Poseida Therapeutics
This page shows the latest Poseida Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Poseida gets Novartis backing for myleoma CAR-T challenger
San Diego firm joins crowded field. Gene-engineering specialist Poseida Therapeutics is launching its own challenger into the crowded CAR-T pipeline for multiple myeloma, and has just gained backing from ... Poseida’s suite of proprietary gene editing
Latest news
-
CAR-Ts take centre stage as ASH18 comes to a close
Another anti-BCMA player – Poseida Therapeutics – presented preliminary data on 19 myeloma patients who had a median of six prior lines of therapy.
-
BCMA in the spotlight as ASH abstracts drop
Biotech, Poseida Therapeutics, CARsgen Therapeutics and Memorial Sloan Kettering Cancer Centre showing impressive efficacy results in multiple myeloma.
-
J&J buys into Alligator's immuno-oncology candidate
Earlier this week, J&J licensed rights to a technology used in the development of another hot area in immuno-oncology - chimeric antigen receptor therapies (CAR-T) to Poseida Therapeutics. ... Poseida wants to screen the molecules for activity against
CAR-Ts take centre stage as ASH18 comes to a close
BCMA in the spotlight as ASH abstracts drop
J&J buys into Alligator's immuno-oncology candidate
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Blockchain for Tracking and Validating Medical Cannabis
- Improving Health Through Integrated & Personalized Patient Care
- Amanda Pritchard becomes NHS England’s first female chief executive
- GSK beats expectations thanks to strong vaccine sales in Q2
- AZ raises full-year guidance after completing Alexion acquisition in Q2
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
- What do NHS changes and the Life Sciences Vision mean for medicines?
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
